Vol. 22 No. 4 (2018)
EXPERIMENTAL STUDIES

Impact of recombinant apolipoprotein A-I on myocardial function in experiment

PDF (Русский)
  • R. Knyazev,
  • N. Trifonova,
  • A. Ryabchenko,
  • M. Kotova,
  • A. Kolpakov,
  • L. Polyakov
R. Knyazev
Federal Research Center of Fundamental and Translational Medicine, Scientific Research Institute of Biochemistry, Novosibirsk, Russian Federation
Bio
N. Trifonova
Federal Research Center of Fundamental and Translational Medicine, Scientific Research Institute of Biochemistry, Novosibirsk, Russian Federation
A. Ryabchenko
Federal Research Center of Fundamental and Translational Medicine, Scientific Research Institute of Biochemistry, Novosibirsk, Russian Federation
M. Kotova
Federal Research Center of Fundamental and Translational Medicine, Scientific Research Institute of Biochemistry, Novosibirsk, Russian Federation
A. Kolpakov
Federal Research Center of Fundamental and Translational Medicine, Scientific Research Institute of Biochemistry, Novosibirsk, Russian Federation; Federal State Novosibirsk Medical University, Novosibirsk, Russian Federation
L. Polyakov
Federal Research Center of Fundamental and Translational Medicine, Scientific Research Institute of Biochemistry, Novosibirsk, Russian Federation
DOI: https://doi.org/10.21688/1681-3472-2018-4-88-94

Published 2018-12-29

Keywords

  • cardiotonic action,
  • inotropic drugs,
  • isolated heart,
  • recombinant apolipoprotein A-I

How to Cite

Knyazev, R., Trifonova, N., Ryabchenko, A., Kotova, M., Kolpakov, A., & Polyakov, L. (2018). Impact of recombinant apolipoprotein A-I on myocardial function in experiment. Patologiya Krovoobrashcheniya I Kardiokhirurgiya, 22(4), 88–94. https://doi.org/10.21688/1681-3472-2018-4-88-94

Copyright (c) 2018 Knyazev R. A., Trifonova N. V., Ryabchenko A. V., Kotova M. V., Kolpakov A. R., Polyakov L. M.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Abstract

Background. It was shown earlier that high-density lipoproteins of rat blood plasma increased the frequency and strength of contraction of an isolated rat heart. The main protein component of high-density lipoproteins, apolipoprotein A-I, isolated from human blood plasma, increased the force of cardiac contractions, with little effect on the frequency. A method for obtaining recombinant apolipoprotein A-I developed at the Institute of Biochemistry allows for facilitating the research into cardiotropic properties of this protein.
Aim. The purpose of this experiment was to study the effect of recombinant apolipoprotein A-I on the performance of an isolated rat heart and to compare it with the action of native apolipoprotein A-I.
Methods. The experiment was performed on Wistar male rats weighing 230–250 g. Isolated hearts of the rats were routinely perfused retrograde, and isovolume pressure in the left ventricle was measured. Recombinant apolipoprotein A-I was obtained in E. coli cells in the form of a chimeric polypeptide followed by the conversion of protein into a mature form of recombinant apolipoprotein A-I.
Results. It was shown that recombinant apolipoprotein A-I with a concentration of 20 μg/ml caused a stable increase in pressure in the left ventricle, while the magnitude of the coronary flow and heart rate changed insignificantly. The maximum inotropic effect was registered for 20 min from the beginning of perfusion and amounted to 147.5% relative to the reference values. It was found out that in the presence of recombinant apolipoprotein A-I, the maximum rate of contraction of the left ventricle increased. At the same time, the diastole had a tendency to increase and was larger in comparison with the initial data at 10 and 20 minutes of perfusion.
Conclusion. The recombinant apolipoprotein A-I under study has cardiotonic properties similar to its native form. However, the mechanism for implementing the inotropic effect requires further study.

Received 3 September 2018. Revised 8 October 2018. Accepted 11 October 2018.

Funding: The study did not have sponsorship.

Conflict of interest: Authors declare no conflict of interest.

Author contributions
Conception and study design: A.R. Kolpakov, R.A. Knyazev
Data collection and analysis: N.V. Trifonova, A.V. Ryabchenko, M.V. Kotova
Critical revision of the article: R.A. Knyazev
Drafting the article R.A. Knyazev
Critical revision of the article: A.R. Kolpakov, L.M. Polyakov
Final approval of the version to be published: R.A. Knyazev, N.V. Trifonova, A.V. Ryabchenko, M.V. Kotova, A.R. Kolpakov, L.M. Polyakov

PDF (Русский)

References

  1. Rone M. B., Fan J., Papadopoulos V. Cholesterol transport in steroid biosynthesis: Role of protein-protein interactions and implications in disease states. Biochim Biophys Acta. 2009;1791(7):646-58. PMID: 19286473; PMCID: PMC2757135. https://doi.org/10.1016/j.bbalip.2009.03.001
  2. Панин Л.Е., Белоногова Ж.И., Князев Р.А., Чешенко И.О. Влияние кортизола в комплексе с липопротеинами очень низкой плотности на развитие гепатомы НА-1 и карциномы Эрлиха. Сибирский онкологический журнал. 2013;(3):43-46. Режим доступа: https://www.siboncoj.ru/jour/article/view/129 [Panin L.E., Belonogova Zh.I., Knyazev R.A., Cheshenko I.O. The effect of cortisol in combination with very low density lipoproteins on the development of hepatoma HA-1 and Ehrlich carcinoma. Siberian Journal of Oncology. 2013;(3):43-46. (In Russ.)]
  3. Poitout V., Robertson R. P. Minireview. Secondary betacell failure in type 2 diabetes. A convergence of glucotoxicity and lipotoxicity. Endocrinology. 2002;143(2):339-42. PMID: 11796484. https://doi.org/10.1210/endo.143.2.8623
  4. Gomaraschi M., Calabresi L., Rossoni G., Gomaraschi M., Calabresi L., Rossoni G., Iametti S., Franceschini G., Stonik J.A., Remaley A.T. Anti-inflammatory and cardioprotective activities of synthetic high-density lipoprotein containing apolipoprotein A-I mimetic peptides. J Pharmacol Exp Ther. 2008;324(2):776-83. PMID: 18042829. https://doi.org/10.1124/jpet.107.129411
  5. Franciscis S., Metzinger L., Serra R. The discovery of novel genomic, transcriptomic, and proteomic biomarkers in cardiovascular and peripheral vascular disease: the state of the art. BioMed Research International. 2016;(2016):1-10. http://dx.doi.org/10.1155/2016/7829174
  6. Majek P., Pecankova K., Maly M., Oravec M., Riedel T., Dyr J.E. N-Glycosylation of apolipoprotein A-I in cardiovascular diseases. Transl Res. 2015;165(2):360-2. PMID: 25262938. https://doi.org/10.1016/j.trsl.2014.09.003
  7. Панин Л.Е., Колпаков А.Р., Князев Р.А., Цирельников Н.И. Кардиотонические свойства липопротеинов высокой плотности. Атеросклероз. 2013;9(2):5-10. Режим доступа: http://sibran.ru/journals/issue.php?ID=153352&ARTICLE_ID=153353 [Panin L.E., Kolpakov A.R., Knyazev R.A., Tsirelnikov N.I. Cardiotonic properties of high density lipoproteins. Ateroskleroz. 2013;9(2):5-10. (In Russ.) Available from: http://sibran.ru/en/journals/issue.php?ID=153352&ARTICLE_ID=153353]
  8. Колпаков А.Р., Князев Р.А., Трифонова Н.В., Поляков Л.М. Кардиотонические свойства аполипопротеина А-I человека. Атеросклероз. 2015;11(4):20-24. Режим доступа: http://sibran.ru/journals/issue.php?ID=165756&ARTICLE_ID=166335 [Kolpakov A.R., Knyazev R.A., Trifonova N.V., Polyakov L.M. The Cardiotonic properties of human apolipoprotein A-I. Ateroskleroz. 2015;11(4):20-24. (In Russ.) Available from: http://sibran.ru/en/journals/issue.php?ID=165756&ARTICLE_ID=166335]
  9. Uehara Y., Chiesa G., Saku K. High-density lipoprotein-targeted therapy and apolipoprotein A-I mimetic peptides. Circ J. 2015;79(12):2523-8. PMID: 26548857. https://doi.org/10.1253/circj.CJ-15-0960
  10. Arciello A., De Marco N., Del Giudice R., Guglielmi F., Pucci P., Relini A., Piccoli R. Insights into the fate of the N‐terminal amyloidogenic polypeptide of ApoA‐I in cultured target cells. Journal of Cellular and Molecular Medicine. 2011;15(12):2652-63. PMID: 21306558; PMCID: PMC4373434. https://doi.org/10.1111/j.1582-4934.2011.01271.x
  11. Капелько В.И., Лакомкин В.Л., Коновалова Г.Г., Цыпленкова В.Г., Тихазе А.К., Ланкин В.З. Острое и пролонгированное действие адриамицина на сократительную функцию и антиоксидантный статус миокарда. Кардиология. 2010;50(12):45-51. [Kapelko V.I., Lakomkin V.L., Konovalova G.G., Tsyplenkova V.G., Tikhaze A.K., Lankin V.Z. Acute and prolonged action of adriamycin on the contractile function and antioxidant status of the myocardium. Cardiology. 2010;50(12):45-51. (In Russ.)]
  12. Ryabchenko A.V., Kotova M.V., Tverdohleb N.V., Knyazev R.A., Polyakov L.M. Production and analysis of biological properties of recombinant human apolipoprotein A-I. Bull Exp Biol Med. 2015;160(1):129-33. PMID: 26612626. https://doi.org/10.1007/s10517-015-3113-4
  13. Kono M., Tanaka T., Tanaka M., Vedhachalam C., Chetty P.S., Nguyen D., Dhanasekaran P., Lund-Katz S., Phillips M.C., Saito H. Disruption of the C-terminal helix by single amino acid deletion is directly responsible for impaired cholesterol efflux ability of apolipoprotein A-I Nichinan. J Lipid Res. 2010;51(4):809-818. PMCID: PMC2842158; PMID: 19805625. https://doi.org/10.1194/jlr.M002113
  14. Petrlova J., Dalla-Riva J., Mörgelin M., Lindahl M., Krupinska E., Stenkula K.G., Voss J.C., Lagerstedt J.O. Secondary structure changes in ApoA-I Milano (R173C) are not accompanied by a decrease in protein stability or solubility. PloS One. 2014;9(4):е96150. PMID: 24755625; PMCID: PMC3995965. https://doi.org/10.1371/journal.pone.0096150
  15. Speidl W.S., Cimmino G., Ibanez B., Elmariah S., Hutter R., Garcia M.J., Fuster V., Goldman M.E., Badimon J.J. Recombinant apolipoprotein A-I Milano rapidly reverses aortic valve stenosis and decreases leaflet inflammation in an experimental rabbit model. Eur Heart J. 2010;31(16):2049-57. PMID: 20304838. https://doi.org/10.1093/eurheartj/ehq064
  16. Nissen S.E., Tsunoda T., Tuzcu E.M., Schoenhagen P., Cooper C.J., Yasin M., Eaton G.M., Lauer M.A., Sheldon W.S., Grines C.L., Halpern S., Crowe T., Blankenship J.C., Kerensky R. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 2003;290(17):2292-300. PMID: 14600188. https://doi.org/10.1001/jama.290.17.2292
  17. Frank P.G., Marcel Y.L. Apolipoprotein A-I: structure–function relationships. J Lipid Res. 2000;41(6):853-872. PMID: 10828078
  18. Schoner W., Scheiner-Bobis G. Endogenous and exogenous cardiac glycosides and their mechanisms of action. Am J Cardiovasc Drugs. 2007;7(3):173-189. PMID: 17610345. https://doi.org/10.2165/00129784-200707030-00004
  19. Schisler J., Lang Ch., Willis M., editors. Endocrinology of the heart in health and disease. Edition integrated, cellular, and molecular endocrinology of the heart. 1st ed. Elsevier. 2016; pp. 41-58.
  20. Панин Л.Е. Биохимические механизмы стресса. Новосибирск: Наука; 1983. 234 с. [Panin L.E. Biochemical mechanisms of stress. Novosibirsk: Science Publ.; 1983. 234 p. (In Russ.)]